• Sachse-Seeboth C, Pfeil J, Sehrt D, Meineke I, Tzvetkov M, Bruns E, Poser W, Vormfelde SV, Brockmöller J (2009):
  Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. CLIN PHARMACOL THER, 85(3): 273-6.
   
• Tzvetkov MV, Vormfelde SV, Balen D, Meineke I, Schmidt T, Sehrt D, Saboli I, Koepsell H, Brockmöller J (2009):
  The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. CLIN PHARMACOL THER (Internet-Ausgabe), 86(3): 299-306.
   
• Vormfelde SV, Brockmöller J, Bauer S, Herchenhein P, Kuon J, Meineke I, Roots I, Kirchheiner J (2009):
  Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. CLIN PHARMACOL THER, 86(1): 54-61.
   
• Kühne A, Sezer O, Heider U, Meineke I, Muhlke S, Niere W, Overbeck T, Hohloch K, Trümper L, Brockmöller J, Kaiser R (2008):
  Population pharmacokinetics of melphalan and glutathione S-transferase polymorphisms in relation to side effects. CLIN PHARMACOL THER, 83(5): 749-57.
   
• Vormfelde SV, Toliat MR, Schirmer M, Meineke I, Nürnberg P, Brockmöller J (2008):
  The polymorphisms Asn130Asp and Val174Ala in OATP1B1 and the CYP2C9 allele 3 independently affect torsemide pharmacokinetics and pharmacodynamics. CLIN PHARMACOL THER, 83(6): 815-7.

Suchworte: Arzneimittelforschung, Pharmakogenetik, Pharmakogenomik, Pharmakoepidemiologie, Arzneimittel-Nebenwirkungen, Therapeutisches Drug-Monitoring, Pharmakokinetik, Klinische Forschung, Arzneimittel